Jean-Pierre Bizzari M.D.


Dr. Bizzari brings extensive experience in oncology drug development. He was Executive Vice President and Global Head of Oncology at Celgene Corporation, responsible for Celgene’s clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan where he oversaw the development and approval of a number of leading oncology products, including REVLIMID® (lenalidomide), VIDAZA®(azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). In addition, he was Chairman of Celgene’s hematology oncology development committee and a member of the company’s management committee. Prior to Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek® (rasburicase). Prior to that he was Vice President, Clinical Development Oncology for Sanofi-Synthelabo and had previously held the same role for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France’s National Cancer Institute and a member of the board of directors of Compugen Ltd., Nordic Nanovector ASA, and Transgene SA. He is a Doctor of Medicine, a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Dr. Bizzari serves on the Nominating and Corporate Governance Committee and the Compensation Committee.